Mackenzie Financial Corp Sells 5,280 Shares of ZimVie Inc. (NASDAQ:ZIMV)

Mackenzie Financial Corp lessened its position in shares of ZimVie Inc. (NASDAQ:ZIMV) by 18.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,233 shares of the company’s stock after selling 5,280 shares during the period. Mackenzie Financial Corp owned about 0.09% of ZimVie worth $412,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Loomis Sayles & Co. L P bought a new position in shares of ZimVie in the 3rd quarter valued at about $4,389,000. LSV Asset Management grew its holdings in shares of ZimVie by 528.6% in the 3rd quarter. LSV Asset Management now owns 753,029 shares of the company’s stock valued at $7,086,000 after acquiring an additional 633,229 shares in the last quarter. Rice Hall James & Associates LLC bought a new position in ZimVie during the third quarter worth about $1,748,000. Acadian Asset Management LLC grew its holdings in ZimVie by 8.5% during the third quarter. Acadian Asset Management LLC now owns 730,436 shares of the company’s stock worth $6,869,000 after purchasing an additional 57,159 shares during the period. Finally, Massachusetts Financial Services Co. MA bought a new position in ZimVie during the third quarter worth about $963,000. Institutional investors own 95.63% of the company’s stock.

ZimVie Trading Up 2.2 %

Shares of ZIMV stock opened at $15.82 on Friday. The firm has a 50 day moving average price of $17.03 and a two-hundred day moving average price of $14.58. The company has a quick ratio of 2.32, a current ratio of 2.78 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $430.64 million, a PE ratio of -1.07 and a beta of 2.18. ZimVie Inc. has a 12-month low of $6.52 and a 12-month high of $20.91.

ZimVie (NASDAQ:ZIMV) last issued its quarterly earnings results on Wednesday, February 28th. The company reported $0.10 earnings per share (EPS) for the quarter. The business had revenue of $113.07 million during the quarter. ZimVie had a positive return on equity of 2.44% and a negative net margin of 51.33%.

Analyst Ratings Changes

ZIMV has been the subject of a number of research analyst reports. Barclays lifted their price target on ZimVie from $13.00 to $16.00 and gave the stock an “underweight” rating in a report on Tuesday, March 5th. Needham & Company LLC reiterated a “hold” rating on shares of ZimVie in a report on Thursday, April 11th.

ZimVie Company Profile

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.